Skip to content
Biodatica
Start free

ARCAGY/ GINECO GROUP

Bordeaux

OncologyantibodyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

1w agoTrial registeredJul 10, 2026Source filing (opens the source filing in a new tab)

Momentum

87no change

Momentum 87 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

672 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Aug 1, 2026

    Ovarian Cancer · NOT_YET_RECRUITING · sponsor: ARCAGY/ GINECO GROUP · Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

    ClinicalTrials.gov · NCT07637851 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Jul 30, 2024

    Ovarian Cancer · RECRUITING · sponsor: ARCAGY/ GINECO GROUP · Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

    ClinicalTrials.gov · NCT06476184 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Feb 21, 2017

    Gestational Trophoblastic Neoplasias (GTN) · COMPLETED · sponsor: Hospices Civils de Lyon · Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias

    ClinicalTrials.gov · NCT03135769 (opens the source filing in a new tab)

  4. Trial

    PHASE1/PHASE2 registered

    Sep 23, 2016

    Recurrent Endometrial Cancer · COMPLETED · sponsor: Hospices Civils de Lyon · Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients

    ClinicalTrials.gov · NCT02755844 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources